Alzamend Neuro Inc (ALZN)
Alzamend Neuro Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in Atlanta, GA, US. The stock last traded at $1.46, down 0.68% on the session, giving a market capitalisation of $5.6M. On trailing twelve-month figures it carries a trailing P/E of -0.50, a net margin of 0.0%. Its beta of 0.19 implies it has historically moved less than the broad market.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro Inc is most often compared with the following Healthcare names: